שווי כולל של החברה: Trevena, Inc. (TRVN)
This chart shows the market price of Trevena, Inc. (TRVN) on the GURU.Markets platform at . The biotech firm is currently suffering from a cash crunch and a lack of revenue, which led to the delisting of its securities. At the same time, Trevena, Inc. (TRVN) holds patents for a secure hospital analgesic protected from replication. The drug's high therapeutic efficacy allows the developer to pursue premium pricing power within the pain management segment.
Trevena, Inc. (TRVN) - פילוחי מדדים ודוחות פיננסיים
Patent protection for selective ligands and stringent FDA oversight make the valuation of Trevena, Inc. (TRVN) dependent on regulatory risks. This enterprise value chart reflects the total acquisition cost of the business by summing market capitalization and net debt (liabilities minus cash), allowing investors to assess the asset's real value beyond standard reporting and identify overpayment in a timely manner.